Tag Archive for 'c reactive protein'
February 28th, 2011 by admin
MedTrust Online and Avantra Biosciences have entered into a partnership to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences’ revolutionary QPDx multiplex immunoassay system.
January 31st, 2011 by admin
Merck Serono is teaming up with France’s Domain Therapeutics to take aim at a new target for Parkinson’s and other neurodegenerative diseases. Domain will contribute compounds developed from their chemical series in exchange for a €2 million upfront, research funding and up to €132 million ($175 million) in milestones for the first two products.
December 30th, 2010 by admin
No, gold-plated liposomes are not a luxury gift that you’d find in your Christmas stocking, but they could someday give cancer patients the gift of life by selectively knocking out cancer cells while leaving healthy ones alone. This holiday gift comes courtesy of Marek Romanowski, an associate professor of biomedical engineering in the University of [...]
December 20th, 2010 by admin
New molecular tools developed at the University of Michigan show promise for “cleansing” the brain of amyloid plaques, implicated in Alzheimer’s disease.
July 29th, 2010 by admin
Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene’s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis’ key drug Abraxane hit certain goals. “These structures are a great way for [...]
July 27th, 2010 by admin
Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued–or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we’ve crunched the numbers to take a closer [...]
July 26th, 2010 by admin
Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly’s current revenue comes from eight drugs that will lose patent protection between now and 2017. ”We have the challenge [...]
July 9th, 2010 by admin
For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it’s often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.
June 25th, 2010 by admin
Lithium is the most effective treatment for bipolar disorder. However, its use is limited because of neurological side effects and a risk for overdose-induced toxicity. Many of the beneficial effects of lithium are mediated by its inhibition of GSK-3 proteins, but whether this is the mechanism underlying its negative effects has not been determined. However, [...]
June 24th, 2010 by admin
Sex “addiction” is a concept that has had particularly high visibility recently with the publicity associated with Tiger Woods. Persons with addictive or compulsive disorders frequently display an inability to inhibit behaviors once they become maladaptive, despite adverse consequences of their behavior. The medial prefrontal cortex (mPFC) is a brain region involved in decision-making and [...]